

## PRESS RELEASE

Berlin, 01.07.2020

# **NUVISAN starts the „INNOVATION CAMPUS BERLIN“ (ICB) with over 400 workplaces**

- **Acquisition and expansion of a complete research unit of Bayer AG**
- **Over 50 additional new hires to date**
- **Pharmaceutical research at a new level**

On the 1st of July, the "INNOVATION CAMPUS BERLIN" (ICB), a subsidiary of NUVISAN GmbH/ Neu-Ulm officially opened. NUVISAN has taken over a large part of the Berlin-based pharmaceutical research unit, focused on the field of small molecule active ingredients, from Bayer AG and agreed on a strategic partnership. "We are looking forward to the strategic expansion of our portfolio. The ICB fits like a missing piece of the puzzle into our overall concept", says Dr. Dietrich Bruchmann, CEO and managing partner of the NUVISAN group.

The NUVISAN group is an international service provider for clinical studies, laboratory services and contract manufacturing for the pharmaceutical industry. NUVISAN operates several sites and clinics in Germany and France. The strategic partnership lays the foundation for a new research entity by NUVISAN in Berlin. The new research center will remain on the Bayer Campus in the "Muellerstrasse", close to Berlin Mitte. As such Bayer is in close proximity to the new partner and can continue to work with familiar and experienced people as well as the known resources of its own research unit. This will also allow Bayer AG to further increase the flexibility of its own research, as indicated when Bayer and NUVISAN jointly announced the collaboration in February.

The new NUVISAN research unit in Berlin with more than 400 workplaces is a fully functional team specialized in small molecule research. The ICB research center has skills and capacities that span the entire drug discovery value chain, including lead Structure Development, Medicinal Chemistry, Pharmacology, Drug Metabolism and Pharmacokinetics and Toxicology.

"With these new capabilities and capacities in the field of drug discovery, we not only welcome a high-performance research team, but also obtain access to excellent specialty know-how and technology and continuously expand the range of services," says Dr. Dietrich Bruchmann, CEO and managing partner of NUVISAN. "The acquisition of the research unit and our commitment to the location on the Bayer campus will create an operational center in the Berlin Science Cluster and allow the combined businesses to significantly accelerate the drug development process from discovery to clinical trials. This enables us to offer all services along the value chain: so to say 'from the molecule to the patient'".

NUVISAN has already recruited more than 50 additional new employees in the weeks before "Day 1" (1st of July, 2020). "The completed service spectrum is already receiving consistently positive feedback from the market. Despite the Corona crisis, we are unwavering in continuing our growth strategy," said Dr. Bruchmann. In this way, NUVISAN is also strengthening Berlin as a business location and health care cluster.

### **Press Contact**

Elmar Rothenfusser  
**NUVISAN GmbH**

Tel.: +49 731 9840 143  
Wegenerstr. 13

Email: [elmar.rothenfusser@nuvisan.com](mailto:elmar.rothenfusser@nuvisan.com)  
D-89321 Neu-Ulm

At the present time, NUVISAN is mainly active in early development, however, "Now we can support all phases of early research," says Dr. Dietrich Bruchmann. NUVISAN ("From the Molecule to the Patient") strives to be able to offer all services along the value chain. Since there was still a need for small molecule research, the new ICB fits perfectly into NUVISAN's growth and strategic plan, says Dr. Bruchmann: "We want to develop into an 'all from a single source' provider not only for the big players in the pharmaceutical industry, but also for innovative Bio-Tech companies and academic (research) institutes. With the ICB, we will become even more complete and will be able to offer more services along the value chain, and even faster".

Bayer and NUVISAN have agreed to work closely together in the coming years to establish the new ICB research center. Some 400 Bayer AG employees will transfer to the new Innovation Campus Berlin. Bruchmann: "In the first few weeks of the transition, we have already got to know and appreciate very committed and highly competent colleagues with excellent specialist knowledge and many years of experience. New Chief Operating Officer Dr. Hans Lindner, previously of Bayer AG: "We have succeeded in ensuring that the entire management team with its expertise and know-how has transferred to NUVISAN. We are particularly proud of this."

The research center is managed by Dr. Hans Lindner (COO) Dr. Dietrich Bruchmann (CEO), Dr. Charlotte Christine Kopitz (Executive Vice President, Head of Therapeutic Research), Dr. Franz von Nussbaum (Executive Vice President, Head of Life Science Chemistry), Dr. Olaf Prien (Executive Vice President, Head of Preclinical Compound Profiling), and Dr. Joerg Fanghaenel (Executive Vice President, Head of Lead Discovery).

### **About NUVISAN**

The NUVISAN group generates sales of approx. € 55 million with currently about 420 highly qualified employees. It originated from LAB GmbH over 40 years ago and has been operating under the name NUVISAN with its headquarters in Neu-Ulm since 2010. The NUVISAN group as a Clinical Research Organization (CRO) and Contract Manufacturing Organization (CDMO) has six sites in Germany and France (Neu-Ulm, Berlin, Grafing, Gauting, Waltrop and Sophia-Antipolis) in addition to monitoring activities with offices in Argentina, Peru and Brazil as well as in the USA. After the takeover, which was completed on 1.7.2020, the NUVISAN Group now employs more than 1.000 people.

### **Further information:**

[www.InnovationCampusBerlin.Com](http://www.InnovationCampusBerlin.Com)

[www.nuvisan.com](http://www.nuvisan.com)

### **Press Contact**

Elmar Rothenfusser  
**NUVISAN GmbH**

Tel.: +49 731 9840 143  
Wegenerstr. 13

Email: [elmar.rothenfusser@nuvisan.com](mailto:elmar.rothenfusser@nuvisan.com)  
D-89321 Neu-Ulm